[{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Carnegie Investment Bank","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2024","type":"Private Placement","leadProduct":"Survodutide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zealand Pharma \/ Carnegie Investment Bank","highestDevelopmentStatusID":"10","companyTruncated":"Zealand Pharma \/ Carnegie Investment Bank"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"Cagrilintide","moa":"||Amylin\/calcitonin receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Cagrilintide","moa":"||Amylin\/calcitonin receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Danske Bank","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Hormone","year":"2023","type":"Private Placement","leadProduct":"Dasiglucagon","moa":"GCGR","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zealand Pharma \/ Danske Bank","highestDevelopmentStatusID":"10","companyTruncated":"Zealand Pharma \/ Danske Bank"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Inapplicable"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : Wegovy (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist, investigated as oral treatment for chronic weight management in adults living with obesity or overweight.

                          Product Name : Wegovy

                          Product Type : Peptide

                          Upfront Cash : Inapplicable

                          May 02, 2025

                          Lead Product(s) : Semaglutide

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : CagriSema is a fixed-dose combination of a long-acting amylin analogue, cagrilintide and semaglutide. It is being investigated for adults with overweight or obesity.

                          Product Name : CagriSema

                          Product Type : Peptide

                          Upfront Cash : Inapplicable

                          March 10, 2025

                          Lead Product(s) : Cagrilintide,Semaglutide

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : Wegovy (semaglutide) is a GLP-1 receptor agonist being investigated in new stregth in adults for chronic weight management & treatment of obesity.

                          Product Name : Wegovy

                          Product Type : Peptide

                          Upfront Cash : Inapplicable

                          January 17, 2025

                          Lead Product(s) : Semaglutide

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : CagriSema is a fixed-dose combination of a long-acting amylin analogue, cagrilintide and semaglutide. It is being investigated for adults with overweight or obesity.

                          Product Name : CagriSema

                          Product Type : Peptide

                          Upfront Cash : Inapplicable

                          December 20, 2024

                          Lead Product(s) : Cagrilintide,Semaglutide

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : The net proceeds will strengthen Zealand’s investment in assets targeting obesity, including BI 456906 (survodutide), a long-acting glucagon/GLP-1 receptor dual agonist for once-weekly administration.

                          Product Name : BI 456906

                          Product Type : Peptide

                          Upfront Cash : Undisclosed

                          August 01, 2024

                          Lead Product(s) : Survodutide

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : Phase III

                          Sponsor : Carnegie Investment Bank

                          Deal Size : $214.0 million

                          Deal Type : Private Placement

                          blank

                          06

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : Wegovy (once-weekly subcutaneous semaglutide 2.4 mg) is a GLP-1 receptor agonist indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adults.

                          Product Name : Wegovy

                          Product Type : Peptide

                          Upfront Cash : Inapplicable

                          August 08, 2023

                          Lead Product(s) : Semaglutide

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : Wegovy® (semaglutide) is targeting GLP-1 receptor prescription medicine used along with diet and exercise to improve blood sugar (glucose) in adults with type 2 diabetes.

                          Product Name : Wegovy

                          Product Type : Peptide

                          Upfront Cash : Inapplicable

                          May 22, 2023

                          Lead Product(s) : Semaglutide

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : The net proceeds will be used for supporting the late stage rare disease assets, including Zegalogue (dasiglucagon), a glucagon analog that acts to increase blood sugar levels, being developed for the treatment of congenital hyperinsulinism.

                          Product Name : Zegalogue

                          Product Type : Hormone

                          Upfront Cash : Undisclosed

                          March 30, 2023

                          Lead Product(s) : Dasiglucagon

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : Phase III

                          Sponsor : Danske Bank

                          Deal Size : Undisclosed

                          Deal Type : Private Placement

                          blank

                          09

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : Northwestern University Feinberg School of Medicine in the US has reported that results from STEP 1 clinical trial of type-2 diabetes drug semaglutide (Ozempic) once weekly was linked to a sustained, clinically relevant reduction in body weight in obese ...

                          Product Name : Wegovy

                          Product Type : Peptide

                          Upfront Cash : Inapplicable

                          October 02, 2021

                          Lead Product(s) : Semaglutide

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : The global 68-week trial is planned for initiation in the second half of 2021 and will investigate the efficacy and safety of oral semaglutide compared to placebo.

                          Product Name : Wegovy

                          Product Type : Peptide

                          Upfront Cash : Inapplicable

                          April 21, 2021

                          Lead Product(s) : Semaglutide

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank